期刊文献+

Death decoy receptor overexpression and increased malignancy risk in colorectal cancer 被引量:3

Death decoy receptor overexpression and increased malignancy risk in colorectal cancer
下载PDF
导出
摘要 AIM: To evaluate human epidermal growth factor receptor 2 (HER2) and death decoy receptor (DcR3) as colorectal cancer prognostic indicators. AIM:To evaluate human epidermal growth factor receptor 2(HER2)and death decoy receptor(DcR3)as colorectal cancer prognostic indicators.METHODS:Colorectal carcinoma specimens from 300patients were analyzed by immunohistochemistry to detect the staining patterns of HER2 and DcR3.Classification of HER2 staining was carried out using the United States Food and Drug Administration semi-quantitative scoring system,with scores of 0 or 1+indicating a tumor-negative(normal expression)status and scores of 2+and 3+indicating a tumor-positive(overexpression)status.Classification of DcR3 was carried out by quantitating the percentage of positive cells within the stained section,with<10%indicating a tumor-negative status and≥10%indicating a tumor-positive status.Correlation of the HER2 and DcR3 staining status with clinicopathological parameters[age,sex,tumor size,differentiation,and the tumor,node,metastasis(pTNM)classification]and survival was statistically assessed.RESULTS:Tumor-positive status for HER2 and DcR3was found in 18.33%and 58.33%of the 300 colorectal carcinoma specimens,respectively.HER2 tumorpositive status showed a significant correlation with tumor size(P=0.003)but not with other clinicopathological parameters.DcR3 tumor-positive status showed a significant correlation with tumor differentiation(P<0.001),pTNM stage(P<0.001),and lymph node metastasis(P<0.001).However,correlation coefficient analysis did not indicate that a statistically significant correlation exists between tumor-positive status for the HER2 and DcR3 overexpression(P=0.236).Patients with specimens classified as DcR3-overexpressing had a significantly worse overall survival(OS)rate than those without DcR3 overexpression(median OS:42.11vs 61.21 mo;HR=50.27,95%CI:44.90-55.64,P<0.001).HER2 overexpression had no significant impact on median OS(35.10 mo vs 45.25 mo;HR=44.40,95%CI:39.32-49.48,P=0.344).However,patients with specimens classified as both HER2-and DcR3-overexpressing had a significantly poorer median OS than those with only HER2 overexpression(31.80 mo vs 52.20 mo;HR=35.10,95%CI:22.04-48.16,P=0.006).CONCLUSION:HER2 overexpression is not an independent prognostic marker of colorectal cancer,but DcR3 overexpression is highly correlated with lymph node metastasis and poor OS.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第15期4440-4445,共6页 世界胃肠病学杂志(英文版)
关键词 Colorectal carcinoma Human epidermal growth factor receptor 2 Death decoy receptor IMMUNOHISTOCHEMISTRY Prognosis Colorectal carcinoma Human epidermal growth factor
  • 相关文献

参考文献6

  • 1Yung-Jue Bang,Eric Van Cutsem,Andrea Feyereislova,Hyun C Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,Giuseppe Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. The Lancet . 2010 (9742)
  • 2Joseph P. Connor,Mildred Felder.Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance[J].Gynecologic Oncology.2008(2)
  • 3GabrieleMild,FelixBachmann,Jean‐LouisBoulay,KatharinaGlatz,UrbanLaffer,AdamLowy,UrsMetzger,JürgenReuter,LuigiTerracciano,RichardHerrmann,ChristophRochlitz.DCR3 locus is a predictive marker for 5‐fluorouracil‐based adjuvant chemotherapy in colorectal cancer[J].Int J Cancer.2002(3)
  • 4Helen Han,Rodney J. Landreneau,Tibetha S. Santucci,Ming Y. Tung,Robin S. Macherey,Stanley E. Shackney,Charles D. Sturgis,Stephen S. Raab,Jan F. Silverman.Prognostic value of immunohistochemical expressions of p53, HER-2/ neu, and bcl-2 in stage I non[ndash ]small-cell lung cancer[J].Human Pathology.2002(1)
  • 5Yasushi Takahama,Yukishige Yamada,Koji Emoto,Heisuke Fujimoto,Tomoyoshi Takayama,Masatoh Ueno,Hideki Uchida,Shuya Hirao,Takashi Mizuno,Yoshiyuki Nakajima.The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas[J].Gastric Cancer.2002(2)
  • 6Jia-Lin Yang PhD,Kim T. Ow MSc,Pamela J. Russell PhD,John M. Ham MD,Dr. Philip J. Crowe PhD.Higher expression of oncoproteins c-myc, c-erbB-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors[J].Annals of Surgical Oncology.1996(6)

共引文献19

同被引文献4

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部